Who is eligible for PBS-subsidised acalabrutinib and venetoclax?

The PBS listing covers adults with CLL or SLL receiving it as a first-line treatment and who meet the clinical eligibility criteria. Eligibility depends on factors including disease characteristics and prior treatment history. Your haematologist or treating specialist will advise on whether the current listing applies to your situation.

What is CLL and how common is it in Australia?

Chronic lymphocytic leukaemia (CLL) is the most common adult leukaemia in Australia, with around 2,600 new diagnoses each year. It is a blood cancer affecting lymphocytes that typically progresses slowly. Small lymphocytic lymphoma (SLL) is closely related. Many people are monitored for years without treatment; others require treatment earlier based on clinical criteria. Management is led by a haematology specialist, with GPs central to coordinating ongoing monitoring and managing treatment side effects.

Acalabrutinib on the PBS: leukaemia treatment drops from $7000 to $25

What just happened

From 1 June 2026, acalabrutinib (Calquence) in combination with venetoclax (Venclexta) became available on Australia’s Pharmaceutical Benefits Scheme as a first-line treatment for chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL). Federal Health Minister Mark Butler announced the listing at the Royal Adelaide Hospital.

The financial shift is stark. Before this listing, acalabrutinib cost approximately $7,000 per script out of pocket. From 1 June, the standard PBS patient contribution applies — $25 concession or $50 general. For the estimated 1,200 Australians per year who are eligible, that is not a marginal price reduction. It is the difference between being able to access a therapy with strong survival evidence and managing a blood cancer on an older regimen because the cost was unreachable.

CLL is the most common adult leukaemia in Australia, diagnosed in around 2,600 people each year. The Leukaemia Foundation Australia has advocated for expanded PBS access to targeted therapies for this disease across multiple PBAC cycles. The new listing arrives after years of submissions and patient advocacy. And it includes something clinically distinctive: unlike the other main targeted therapy class used in CLL, this regimen ends.

The acalabrutinib–venetoclax course runs for approximately 12 months. Patients complete treatment and stop. This contrasts with indefinite continuous BTK inhibitor therapy — ibrutinib, zanubrutinib — which continues until disease progression or intolerance. The PBS listing changes effective 1 June 2026 reflect the Pharmaceutical Benefits Advisory Committee’s assessment that this fixed-duration, high-efficacy approach represents a meaningful advance for eligible patients.

The both-and

This is a genuine access win for people with CLL in Australia. It is also a story about a system that routinely makes patients with life-threatening diagnoses wait years and run advocacy campaigns to access medicines with robust phase 3 evidence. Both are true simultaneously.

The clinical evidence is solid

The PBS listing is based on data from the AMPLIFY trial, which tested acalabrutinib plus venetoclax against standard chemoimmunotherapy (FCR or BR regimens) in previously untreated CLL. Trial data showed 94% three-year overall survival in the targeted combination arm versus just over 80% in the chemoimmunotherapy arm — a meaningful difference in a disease where most patients are older adults with comorbidities. The combination also achieved high rates of undetectable minimal residual disease (uMRD), the deepest measurable response, which is the rationale for treating to this endpoint and stopping.

The dual mechanism matters for that depth of response. Acalabrutinib inhibits Bruton’s tyrosine kinase (BTK), blocking B-cell receptor signalling — a survival pathway for CLL cells. Venetoclax inhibits BCL-2, blocking the intrinsic apoptosis pathway. Together they attack CLL through different biological routes, which is why the combination achieves remission rates that neither drug alone can match consistently.

CLL has a long natural history. Many people are diagnosed in their 60s or 70s and monitored without treatment for years. When treatment is required, the choice of first-line regimen matters because it shapes the options available at relapse. Having access to a fixed-duration, MRD-targeted combination from the outset — at an accessible cost — is clinically significant for that long-game decision.

The fixed-duration model changes the patient experience

Indefinite oral targeted therapy is a specific kind of chronic condition burden. It means daily medication, ongoing prescription management, potential side effects that extend for years, and an open-ended treatment horizon. The fixed-duration model changes that frame substantially. Twelve months, a clear end date, a meaningful chance of sustained remission after stopping: for an older adult who was weighing the prospect of daily medication until disease progression, this is different in kind, not just degree.

There is no guarantee of long-term remission after stopping — CLL typically returns, and a proportion of patients will need further treatment. But the concept of a course that ends rather than a treatment that continues indefinitely is different in how it integrates into a person’s life, particularly for older adults managing other health conditions alongside their leukaemia.

The access history is worth naming

This listing follows a familiar pattern for blood cancer targeted therapies in Australia. Before ibrutinib was PBS-listed for CLL in 2017, relapsed patients had limited options. Before venetoclax monotherapy was listed, patients paid full price or accessed compassionate use programs. The years between a drug receiving TGA approval and achieving PBS listing are years during which patients either pay full cost, access trial programs, or go without.

The June 2026 announcement is genuinely worth celebrating for the 1,200 people per year who now access this combination at $25 per script. The underlying timeline is worth remembering when evaluating how the system works for people with serious diagnoses.

2 cents

If you or a family member have been diagnosed with CLL or SLL in Australia, this PBS listing is directly relevant to a conversation about first-line treatment options. Acalabrutinib plus venetoclax is now a subsidised option from 1 June, and your haematology specialist can advise on whether you meet the current eligibility criteria and whether this regimen is appropriate for your clinical picture.

If you are on watchful waiting (active surveillance without treatment) and approaching a decision point about when to start, this change in accessible options is worth factoring into that conversation — ideally before the decision point arrives rather than at it.

GPs play a central role in CLL management despite it being haematologist-led: infection surveillance, monitoring for treatment side effects, managing comorbidities, and supporting the patient through a disease that moves on a years-long timescale. This listing does not change that role, but it expands the toolkit that haematology teams can offer.

This is general information about a PBS listing. Individual eligibility, treatment timing, and regimen choice are clinical decisions made in partnership with a haematology specialist.

Verdict

Verdict: yes — worth knowing about.

The acalabrutinib–venetoclax PBS listing removes a cost barrier that was, practically speaking, a prohibition on this therapy for most eligible Australians. The clinical evidence is solid. The fixed-duration model is meaningful for a population managing a long-term disease trajectory. And the access story — both the gain and the years it took to arrive — is the fuller picture.